High Throughput Process Development

High Throughput Process Development

Global High Throughput Process Development Market to Reach US$24.6 Billion by 2030

The global market for High Throughput Process Development estimated at US$14.1 Billion in the year 2023, is expected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2023-2030. Monoclonal Antibodies Molecule Type, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$17.8 Billion by the end of the analysis period. Growth in the Other Molecule Types segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 12.6% CAGR

The High Throughput Process Development market in the U.S. is estimated at US$3.7 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global High Throughput Process Development Market - Key Trends and Drivers Summarized

Why Is High Throughput Process Development Essential for Biopharmaceuticals?

High throughput process development (HTPD) is a critical tool in the biopharmaceutical industry, enabling faster, more efficient development of biologic drugs. HTPD involves the use of automated, miniaturized experiments that allow researchers to test multiple process conditions simultaneously, significantly accelerating the optimization of production processes for therapeutic proteins, vaccines, and monoclonal antibodies. The ability to screen numerous variables at once reduces the time and resources needed to scale up bioprocesses, from lab-scale to commercial manufacturing. As biopharmaceutical companies face increasing pressure to reduce costs and bring therapies to market faster, HTPD has become indispensable in ensuring both process efficiency and product quality.

How Are Technological Innovations Shaping High Throughput Process Development?

Technological innovations, particularly in automation, robotics, and data analytics, have revolutionized high throughput process development. Automation systems now allow for the simultaneous running of hundreds of experiments, enabling researchers to optimize cell culture conditions, purification processes, and formulation strategies more efficiently. The integration of advanced data analytics and machine learning into HTPD platforms has further enhanced process optimization, allowing for predictive modeling and real-time decision-making. Microfluidic technologies, which allow for the precise control of small volumes of liquids, are also playing a critical role in reducing reagent use and increasing the speed of bioprocess optimization. These technologies are enabling biopharmaceutical companies to streamline their development timelines and reduce production costs.

How Do Market Segments Define the Growth of the High Throughput Process Development Market?

Product types include consumables, software, and instruments, with consumables like reagents and microplates holding the largest market share due to their constant need in HTPD workflows. Services such as contract research and process development outsourcing are also expanding, as biopharmaceutical companies increasingly seek external expertise to accelerate drug development. The biopharmaceutical industry, particularly companies focused on biologics such as monoclonal antibodies, is the primary end-user of HTPD, as it enables rapid scale-up from R&D to manufacturing. Other key users include academic and research institutes involved in biotechnology research.

What Factors Are Driving the Growth in the High Throughput Process Development Market?

The growth in the high throughput process development market is driven by several factors, including the increasing complexity of biologic drugs, the rising demand for personalized medicines, and advancements in automation and data analytics. As the biopharmaceutical industry shifts toward more complex therapeutics, such as gene and cell therapies, the need for efficient process optimization is more critical than ever. HTPD allows companies to streamline the development of these therapies, reducing both time and costs. The growing demand for biosimilars, which require rapid process development to compete with branded biologics, is also contributing to market growth. Additionally, the adoption of automation and machine learning in process development is further enhancing the efficiency and accuracy of bioprocess optimization, driving the market’s expansion.

Select Competitors (Total 33 Featured) -

• Agilent Technologies
• Aurora Biomed
• Axxam S.P.A.
• Bio-Rad Laboratories
• Danaher Corporation
• Eppendorf
• GE Healthcare
• Hamilton Company
• Merck Millipore
• Perkinelmer
• Sartorius Stedim Biotech
• Tecan Group
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.